ClinicalTrials.gg
CompletedNCT00882687Updated Jun 11, 2021Results posted

Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis

A Phase 2 interventional study of Lifitegrast and Placebo in Allergic Conjunctivitis, sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.

Enrollment
60th of 90
60 · median 94
Started
2009
with 7 others
Phase 2
25 of 95
4 open now
Registered
21st of 95
by date

Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 60th largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2009, is one of 25 in phase 2, and was the 21st registered.

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.

Browse Conjunctivitis, Allergic studies →

Open to participants now

6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Conjunctivitis, Allergic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis

03

Conditions studied

  • Allergic Conjunctivitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form and HIPAA document
  • Willing and able to comply with all study procedures
  • Be at least 18 years of age at the time of enrollment
  • 20/40 vision, or better, in each eye
  • History of ocular allergies, and a positive skin and ocular allergic reaction to allergens
  • A negative urine pregnancy test if female of and must use adequate throughout the study period

Exclusion criteria

Exclusion Criteria:

  • Preauricular lymphadenopathy or any ocular condition that could affect study parameters (particularly, glaucoma, diabetic retinopathy, blepharitis, follicular conjunctivitis and iritis)
  • Have had any ocular infection within the last 30 days
  • A positive diagnosis of moderate to severe dry eye syndrome (i.e., requiring daily use of artificial tears)
  • Any significant illness that could be expected to interfere with study parameters
  • Manifest signs or symptoms of clinically active allergic conjunctivitis in either eye
  • Use of any product or device within one month prior to Visit 1 or during the study period
  • Concomitant use of any prohibited medication (antihistamines, , all ocular medications or anti-allergic therapies) during the trial or within the
  • Any blood donation or significant loss of blood within 56 days of Visit 1
  • Any history of disease, immunodeficiency disorder, positive , , C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant. Any known history of iritis/uveitis, glaucoma, or other chronic ophthalmologic disorder other than allergic conjunctivitis
  • History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 3 months prior to Visit 1
  • Known history of alcohol abuse and/or drug abuse
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    0.1% Lifitegrast

    Drug: Lifitegrast

  • Experimental
    1.0% Lifitegrast

    Drug: Lifitegrast

  • Experimental
    5.0% Lifitegrast

    Drug: Lifitegrast

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Ophthalmic Solution

    Also known as: SAR 1118

  • OtherPlacebo

    Ophthalmic Solution

06

What researchers measure

Primary outcomes

  1. Ocular Itching at Day 7 (7 Minutes Post Conjunctival Allergen Challenge [CAC 6])

    Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching. CAC is an initial titration challenge to determine the appropriate allergen and lowest concentration of allergen that produced a positive bilateral allergic response for each subject, defined as ≥ 2 score (0-4 point scale) in ocular itching and conjunctival redness within 10 minutes of the last titration of allergen.

    Time frame: Baseline to Day 7 (7 minutes post CAC 6)

  2. Ocular Itching at Day 14 (7 Minutes Post CAC 9)

    Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching.

    Time frame: Baseline to Day 14 (7 minutes post CAC 9)

  3. Conjunctival Redness at Day 7 (20 Minutes Post CAC 6)

    Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.

    Time frame: Baseline to Day 7 (20 minutes post CAC 6)

  4. Conjunctival Redness at Day 14 (20 Minutes Post CAC 9)

    Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.

    Time frame: Baseline to Day 14 (20 minutes post CAC 9)

Secondary outcomes

  1. Ocular Itching at Day 6 (CAC 4), 5 (CAC 7)

    Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching.

    Time frame: Baseline to Day 6 (CAC 4), Day 13 (CAC 7) 7 minutes post CAC

  2. Conjunctival Redness at Day 6 (CAC 4), 5 (CAC 7)

    Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.

    Time frame: Baseline to Day 6 (CAC 4), Day 13 (CAC 7) at 20 minutes post CAC

07

Results

Posted Feb 24, 2017

Participant flow

Participant flow — Overall Study
MilestoneLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Started15151515
Completed13131213
Not completed2232

Outcome measures

PrimaryOcular Itching at Day 7 (7 Minutes Post Conjunctival Allergen Challenge [CAC 6])

Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching. CAC is an initial titration challenge to determine the appropriate allergen and lowest concentration of allergen that produced a positive bilateral allergic response for each subject, defined as ≥ 2 score (0-4 point scale) in ocular itching and conjunctival redness within 10 minutes of the last titration of allergen.

Time frame:
Baseline to Day 7 (7 minutes post CAC 6)
Reported as:
Mean · units on a scale
Ocular Itching at Day 7 (7 Minutes Post Conjunctival Allergen Challenge [CAC 6])
units on a scaleLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Ocular Itching at Day 7 (7 Minutes Post Conjunctival Allergen Challenge [CAC 6])2.65 ± 0.7312.68 ± 1.0963.07 ± 0.8372.88 ± 0.410
Statistical analysis
  • Lifitegrast 0.1% vs Placebo · Wilcoxon rank-sum test · p = 0.3235
  • Lifitegrast 1.0% vs Placebo · Wilcoxon rank-sum test · p = 0.9144
  • Lifitegrast 5.0% vs Placebo · Wilcoxon rank-sum test · p = 0.3324
PrimaryOcular Itching at Day 14 (7 Minutes Post CAC 9)

Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching.

Time frame:
Baseline to Day 14 (7 minutes post CAC 9)
Reported as:
Mean · units on a scale
Ocular Itching at Day 14 (7 Minutes Post CAC 9)
units on a scaleLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Ocular Itching at Day 14 (7 Minutes Post CAC 9)2.28 ± 1.0432.50 ± 1.1912.63 ± 0.9682.12 ± 0.737
Statistical analysis
  • Lifitegrast 0.1% vs Placebo · Wilcoxon rank-sum test · p = 0.5846
  • Lifitegrast 1.0% vs Placebo · Wilcoxon rank-sum test · p = 0.1493
  • Lifitegrast 5.0% vs Placebo · Wilcoxon rank-sum test · p = 0.0404
PrimaryConjunctival Redness at Day 7 (20 Minutes Post CAC 6)

Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.

Time frame:
Baseline to Day 7 (20 minutes post CAC 6)
Reported as:
Mean · units on a scale
Conjunctival Redness at Day 7 (20 Minutes Post CAC 6)
units on a scaleLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Conjunctival Redness at Day 7 (20 Minutes Post CAC 6)2.27 ± 0.4582.48 ± 0.4062.57 ± 0.4772.52 ± 0.427
Statistical analysis
  • Lifitegrast 0.1% vs Placebo · Wilcoxon rank-sum test · p = 0.0578
  • Lifitegrast 1.0% vs Placebo · Wilcoxon rank-sum test · p = 0.8988
  • Lifitegrast 5.0% vs Placebo · Wilcoxon rank-sum test · p = 0.4709
PrimaryConjunctival Redness at Day 14 (20 Minutes Post CAC 9)

Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.

Time frame:
Baseline to Day 14 (20 minutes post CAC 9)
Reported as:
Mean · units on a scale
Conjunctival Redness at Day 14 (20 Minutes Post CAC 9)
units on a scaleLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Conjunctival Redness at Day 14 (20 Minutes Post CAC 9)1.92 ± 0.6862.42 ± 0.3972.38 ± 0.3992.17 ± 0.652
Statistical analysis
  • Lifitegrast 0.1% vs Placebo · Wilcoxon rank-sum test · p = 0.1773
  • Lifitegrast 1.0% vs Placebo · Wilcoxon rank-sum test · p = 0.4222
  • Lifitegrast 5.0% vs Placebo · Wilcoxon rank-sum test · p = 0.4326
SecondaryOcular Itching at Day 6 (CAC 4), 5 (CAC 7)

Ocular Itching was evaluated by participants and graded with Ophthalmic Research Associates, Inc. (ORA) Scale with the score ranged from 0 to 4 (0=none; 0.5=intermittent tickle in the cornea; 1=intermittent tickle more than just the cornea; 1.5=intermittent all-over tickling sensation; 2=mild conscious itch without desire to rub; 2.5=moderate, diffuse continuous itch with desire to rub; 3=severe itch with desire to rub; 3.5=severe itch improved with minimal rubbing; 4=incapacitating itch with an irresistible urge to rub) with 0.5 point increments allowed, and lower scores indicates lesser ocular itching.

Time frame:
Baseline to Day 6 (CAC 4), Day 13 (CAC 7) 7 minutes post CAC
Reported as:
Mean · units on a scale
Ocular Itching at Day 6 (CAC 4), 5 (CAC 7)
units on a scaleLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Visit 3: 7 minutes post CAC 42.83 ± 0.5642.37 ± 0.8863.02 ± 0.6442.82 ± 0.395
Visit 5: 7 minutes post CAC 72.42 ± 1.0842.62 ± 0.7782.63 ± 0.9722.38 ± 0.388
SecondaryConjunctival Redness at Day 6 (CAC 4), 5 (CAC 7)

Conjunctival Redness was evaluated by an investigator with slit lamp and graded with ORA Scale with the score ranged from 0 to 4 (0=none; 1=mild-slightly dilated blood vessels; color of vessels is typically pink; can be quadrantal; 2=moderate-more apparent dilation of blood vessels; vessel color is more intense (redder); involves the majority of the vessel bed; 3=severe-numerous and obvious dilated blood vessels; in the absence of chemosis the color is deep red, may be less red or pink in presence of chemosis, is not quadrantic; 4=extremely severe-large, numerous, dilated blood vessels characterized by unusually severe deep red color, regardless of grade of chemosis, which involves the entire vessel bed) with 0.5 point increments allowed, and lower scores indicates reduction in the conjunctival redness.

Time frame:
Baseline to Day 6 (CAC 4), Day 13 (CAC 7) at 20 minutes post CAC
Reported as:
Mean · units on a scale
Conjunctival Redness at Day 6 (CAC 4), 5 (CAC 7)
units on a scaleLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Visit 3: 20 minutes post CAC 41.82 ± 0.5942.15 ± 0.7252.25 ± 0.6052.25 ± 0.433
Visit 5: 20 minutes post CAC 71.37 ± 0.9112.15 ± 0.7491.62 ± 1.0261.77 ± 0.863

Adverse events

Collected over Up to Day 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lifitegrast 0.1%—0/15 (0%)6/15 (40%)
Lifitegrast 1.0%—0/15 (0%)7/15 (46.7%)
Lifitegrast 5.0%—0/15 (0%)12/15 (80%)
Placebo—1/15 (6.7%)6/15 (40%)
Most frequent serious events
Most frequent serious events
EventLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Traumatic haematomaInjury, poisoning and procedural complications0/150/150/151/15
Most frequent other events
Most frequent other events
EventLifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%Placebo
Eye DisordersEye disorders4/156/159/150/15
General Discomfort and Administration Site ConditionsGeneral disorders4/152/156/156/15

Baseline characteristics

Intent-to-treat (ITT) population included data from all randomized participants.

Age, Continuous
Age, Continuous(years)Lifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%PlaceboTotal
Mean41.67 ± 15.20737.67 ± 12.61345.33 ± 15.89139.13 ± 12.21240.95 ± 14.019
Sex: Female, Male
Sex: Female, Male(Participants)Lifitegrast 0.1%Lifitegrast 1.0%Lifitegrast 5.0%PlaceboTotal
Female959629
Male6106931
08

Study locations

1 site
  • Ora
    Andover, Massachusetts 01810, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2009 to primary completion in May 2009, 0 months.

Results were first posted in Feb 2017, 7 years 9 months after primary completion. A results delay was requested in Jul 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2009
First posted
Apr 16, 2009
StartActual
Apr 24, 2009
Primary completionActual
May 10, 2009
CompletionActual
May 10, 2009
Results delay requested
Jul 2, 2013
Results first posted
Feb 24, 2017
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00882687
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Apr 16, 2009
Start date
Apr 24, 2009
Primary completion
May 10, 2009
Completion
May 10, 2009
Results posted
Feb 24, 2017
Last update
Jun 11, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lifitegrast

Start the discussion